Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • mRNA technology

    - PMLiVE

    Sanofi unveils $20bn US investment to boost R&D and manufacturing presence

    The company is the latest major drugmaker to announce a significant investment in the country

    Biogen Idec building

    Biogen unveils plans for new global headquarters and R&D hub in US

    The company is expecting to relocate its Cambridge-based employees to the new site in 2028

    - PMLiVE

    AstraZeneca announces $2.5bn investment in China to boost R&D capabilities

    The funds will go towards a new global research and development centre in Beijing’s BioPark

    - PMLiVE

    Ipsen announces launch of new UK headquarters in London life sciences community

    The Paddington site will serve as one of the company’s three global hubs

    - PMLiVE

    ABPI publishes manifesto for government to accelerate UK life sciences industry

    The trade association has called on political parties to commit to three broad goals and requirements

    - PMLiVE

    UK’s Autumn Budget details measures to boost life sciences sector

    The new budget will aim to advance research and manufacturing in the UK

    - PMLiVE

    ABPI report shows improvement in UK industry clinical trial performance

    The data showed a 15% increase in annual recruitment to UK industry clinical trials

    - PMLiVE

    BioIndustry Association reveals how UK is set to become a global leader in mRNA

    Several companies and organisations have supported the development of mRNA

    - PMLiVE

    mRNA technology for universal flu vaccine shows early promise in US study

    The evolving nature of influenza viruses requires frequent reformulation of vaccines

    - PMLiVE

    Pfizer doses first patients with mRNA-based influenza vaccine

    Available vaccine strains that match circulating influenza viruses offer only 40%-60% protection

    - PMLiVE

    Sanofi to buy acne specialist Origimm

    The acquisition brings Origimm’s ORI-001 vaccine candidate against acne vulgaris into Sanofi’s vaccine pipeline, building its strength in mRNA technology

    dengue fever mosquito

    BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine

    The company aims to develop a vaccine candidate and also boost mRNA manufacturing capabilities on the African continent

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links